# Aptimmune Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aptimmune-biologics

- Industry: Biotechnology
- Headquarters: Champaign, US
- Website: www.aptimmune.com
- Total disclosed funding: $2.8M
- Latest round: Series A (Jul 9, 2015)
- Investors on record: 2

## About

Aptimmune Biologics focuses on developing advanced mucosal vaccines targeting swine diseases, specifically the Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), to enhance livestock health and productivity.Aptimmune Biologics specializes in creating innovative vaccines combating swine pathogens. Founded by Federico Zuckermann and headquartered in Champaign, US, the company secured USD 2.75 mn in Series A funding in July 2015, led by Arsenal Capital Partners, with participation from Fox Ventures. No significant pivots or changes in operations have been noted since its inception.Aptimmune Biologics develops mucosal vaccines aimed at swine diseases, particularly focusing on Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Their products utilize cutting-edge vaccination technology to improve livestock health, making them essential for veterinary professionals and swine producers across North America, Europe, and select regions in Asia. The company collaborates with academic and industry partners to enhance its vaccine technology and market presence.Aptimmune Biologics generates revenue through direct sales of its vaccines, targeting veterinary professionals and swine producers for herd health management. The company engages in B2B transactions, supplying large-scale veterinary distributors and agricultural firms with bulk vaccines. Additional revenue avenues may include subscription services for ongoing support regarding vaccine efficacy. Their collaborations, including those with Kemin Industries, bolster their visibility and revenue potential in the agricultural biotech sector.Aptimmune Biologics plans to leverage the recent Series A funding of USD 2.75 mn to enhance product development and market reach. Upcoming new vaccines are in the pipeline, with plans for expansion into European and Asian markets by 2025. The recent funding will support these initiatives, ensuring the company can address the growing needs of the swine industry effectively.

## Funding rounds

- Series A, Jul 9, 2015, $2.8M — Arsenal Capital Partners, Fox Ventures

## Investors

- Arsenal Capital Partners (https://capitalatlas.ai/funds/arsenal-capital-partners) — Series A
- Fox Ventures (https://capitalatlas.ai/funds/fox-ventures) — Series A